MONTREAL, Oct. 09, 2024 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on development and commercialization of innovative therapies, today announced three upcoming poster presentations at IDWeek 2024, taking place October 16-19 in Los Angeles, Calif.
One poster presents data linking excess visceral abdominal fat (EVAF) to increased cardiovascular risk in people with HIV, while a second poster documents how use of tesamorelin, a growth hormone-releasing factor (GHRF) analog, to reduce EVAF can lower cardiovascular disease risk in persons with HIV. Another poster reports on the study design and baseline characteristics of the PROMISE-US trial, an observational, real-world study of ibalizumab, a CD4-directed post-attachment inhibitor of HIV, in heavily treatment-experienced patients with multidrug resistance.
“The IDWeek poster presentations shed new light on important medical issues facing people with HIV,” said Christian Marsolais, Ph.D., Senior Vice President and Chief Medical Officer of Theratechnologies. “As people live longer with HIV and with greater exposure to anti-retroviral medicines, they may experience higher amounts of excess visceral abdominal fat and risk multidrug resistance. We look forward to sharing our findings with HIV clinicians and researchers at this premier meeting on infectious disease.”
Theratechnologies will present the following posters at IDWeek 2024:
Title: Impact of Tesamorelin on Cardiovascular Disease Risk Prediction Scores in Phase 3 Studies Treatment Arms: Subanalysis
Title: Cardiovascular Risk Scores and Insulin Resistance are Higher with Excess Visceral Abdominal Fat in People with HIV in the Modern Antiretroviral (ART) Era.
Title: A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes with and without Ibalizumab in a Real-World Setting: United States (PROMISE-US) Study Design and Baseline Characteristics
IDWeek is the joint annual meeting of the Infectious Diseases Society of America, the Society for Healthcare Epidemiology of America, the HIV Medicine Association, the Pediatric Infectious Diseases Society and the Society of Infectious Diseases Pharmacists.
About Theratechnologies
Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company’s website at www.theratech.com, on SEDAR at www.sedarplus.ca and on EDGAR at www.sec.gov. Follow Theratechnologies on Linkedin and Twitter.
Forward-Looking Information
This press release contains forward-looking statements and forward-looking information (collectively, the “Forward-Looking Statements”), within the meaning of applicable securities laws, that are based on our management’s beliefs and assumptions and on information currently available to our management. You can identify Forward-Looking Statements by terms such as “may”, “will”, “should”, “could”, “promising”, “would”, “outlook”, “believe”, “plan”, “envisage”, “anticipate”, “expect” and “estimate”, or the negatives of these terms, or variations of them. The Forward-Looking Statements contained in this press release include, but are not limited to, statements regarding the longevity of people with HIV and its relationship with increased excess visceral abdominal fat and the risk of multi-drug resistance. Forward-looking statements involve a number of assumptions, risks and uncertainties. The Company refers current and potential investors to the “Risk Factors” section of the Company’s Form 20-F dated February 21, 2024 available on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov under Theratechnologies’ public filings. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward-looking statements. Forward-Looking Statements reflect current expectations regarding future events and speak only as of the date of this press release and represent the Company’s expectations as of that date.
The Company undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise, except as may be required by applicable law.
Contacts:
Media inquiries:
Julie Schneiderman
Senior Director, Communications & Corporate Affairs
communications@theratech.com
1-514-336-7800
Investor Inquiries:
Philippe Dubuc
Senior Vice President and Chief Financial Officer
pdubuc@theratech.com
438-315-6608
Most vulnerable sectors include pharmaceuticals, medical devices, agriculture, defense and aerospace WASHINGTON, Oct. 10, 2024…
MIDDLETON, Wis., Oct. 10, 2024 /PRNewswire/ -- Natus Medical Incorporated announced it has submitted an…
Event Draws 100+ Health Systems for 40+ Sessions Focused on Enhancing the Patient Experience Through…
New MammoScreen® AI delivers a comprehensive suite of features including breast density and pre-reporting, creating…
Week Begins with In-Depth Discussions on Life Science Trends and Celebrates Innovative Products that Have…
The enhanced employee sentiment tool equips employees and leaders to address stress, burnout, disengagement, and…